The Hypertension in the Very Elderly Trial (HYVET) is a randomized double-blind trial of active antihypertensive treatment (indapamide 1.5 mg sustained release +/-2-4 mg perindopril) vs placebo in participants over the age of 80 years with a systolic blood pressure (SBP) of 160-199 mmHg during a placebo run-in period plus a diastolic blood pressure (DBP) of<110 mmHg. The trial has completed with 3845 subjects randomized and we report the baseline characteristics. The participants were a healthy group. The numbers smoking, drinking alcohol and having previous cardiovascular events were low, and their hypertensive status was not usually associated with the metabolic syndrome; 1.0% of the whole group had a total cholesterol over 8.0 mmol/l, 1....
The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of ...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...
The Hypertension in the Very Elderly Trial (HYVET) is a randomized double-blind trial of active anti...
A number of trials and meta-analyses have demonstrated clear benefits of blood pressure (BP) reducti...
BACKGROUND: It is well known that the global population is aging and that those over the age of 80 a...
To report blood pressure control in the Hypertension in the Very Elderly Trial, a placebo-controlled...
BACKGROUND: The results of the Hypertension in the Very Elderly Trial showed positive benefits from ...
Contains fulltext : 69201.pdf (publisher's version ) (Closed access)The 'Hypertens...
Background: Treatment for hypertension with antihypertensive medication has been shown to reduce str...
BACKGROUND AND OBJECTIVE: Randomised, controlled trials and population studies have suggested a link...
White coat hypertension is considered to be a benign condition that does not require antihypertensiv...
OBJECTIVE: To assess if very elderly people with hypertension obtain early benefit from antihyperten...
<p>Data are mean (SD) unless otherwise indicated. Hypertension is defined as either reporting use of...
Objective. To determine whether antihypertensive therapy reduces the risk of stroke among elderly pa...
The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of ...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...
The Hypertension in the Very Elderly Trial (HYVET) is a randomized double-blind trial of active anti...
A number of trials and meta-analyses have demonstrated clear benefits of blood pressure (BP) reducti...
BACKGROUND: It is well known that the global population is aging and that those over the age of 80 a...
To report blood pressure control in the Hypertension in the Very Elderly Trial, a placebo-controlled...
BACKGROUND: The results of the Hypertension in the Very Elderly Trial showed positive benefits from ...
Contains fulltext : 69201.pdf (publisher's version ) (Closed access)The 'Hypertens...
Background: Treatment for hypertension with antihypertensive medication has been shown to reduce str...
BACKGROUND AND OBJECTIVE: Randomised, controlled trials and population studies have suggested a link...
White coat hypertension is considered to be a benign condition that does not require antihypertensiv...
OBJECTIVE: To assess if very elderly people with hypertension obtain early benefit from antihyperten...
<p>Data are mean (SD) unless otherwise indicated. Hypertension is defined as either reporting use of...
Objective. To determine whether antihypertensive therapy reduces the risk of stroke among elderly pa...
The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of ...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...
Objective To assess if very elderly people with hypertension obtain early benefit from antihypertens...